Regional Native American Community Networks Program (RNACNP)

Innovations in Enhancing Colorectal Cancer Screening

Aim: Determine the overall effectiveness of a targeted digital messaging intervention at improving colorectal cancer (CRC) screening rates compared to care as usual.

Hypothesis: Screening rates will be higher for patients who receive the digital messaging intervention, compared to the control group in which patients receive care as usual.

Study Overview

• Status: Completed
• Conditions: Colorectal Cancer
• Intervention / Treatment: Behavioral: Lifestyle, screening

Detailed Description

Native People for Cancer Control is one of the projects under Partnerships for Native Health, and is 1 of 23 Community Networks Programs funded by the National Cancer Institute. The aim of Native People for Cancer Control is to reduce cancer health disparities by conducting training, research, education and outreach, in collaboration with American Indian and Alaska Native communities. We do this work in partnership with Native people, communities, and organizations in an 8-state area, including: Alaska, Washington, Wyoming, Oregon, Idaho, Montana, North Dakota, and South Dakota. Our program consists of 4 cores:

Administrative Core: assists with grant administration, budgeting, sub-contracts with Tribes, program planning, and reporting.

Outreach/Education Core: assists with cancer education, outreach, health promotion, and cancer prevention activities among urban and rural AI/AN people.

Training Core: builds capacity for Native faculty-level investigators, and students, to conduct research.

Research Core: conducts community-based participatory research on colorectal cancer screening, health literacy, health communication, and cancer risk factors among American Indian and Alaska Native people.

The main research project under Native People for Cancer Control is titled, "Innovations in Enhancing Colorectal Cancer Screening". The goal of this project is to develop, implement, and evaluate a community wide, multi-media campaign to improve colorectal cancer screening among American Indians and Alaska Natives in 3 communities.

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Washington
    • Pullman, Washington, United States, 99164-4820
      • Washington State University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• AI/AN
• Age 50-75
• Active clinical patient

Exclusion Criteria:

• Not AI/AN

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Interventional Model: Crossover Assignment

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Text Messaging	Behavioral: Lifestyle, screening

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Colorectal Cancer Screening, beginning age 50	9 month intervention

Collaborators and Investigators

• Sponsor: Washington State University

Study record dates

Study Major Dates

• Study Start: September 1, 2010
• Primary Completion (Actual): August 1, 2015
• Study Completion (Actual): August 1, 2015

Study Registration Dates

• First Submitted: June 15, 2016
• First Submitted That Met QC Criteria: July 20, 2016
• First Posted (Estimate): July 25, 2016

Study Record Updates

• Last Update Posted (Actual): October 15, 2018
• Last Update Submitted That Met QC Criteria: October 10, 2018
• Last Verified: June 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms
• Other Study ID Numbers: U54CA153498 (U.S. NIH Grant/Contract)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No